These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Inhibitor screening of pharmacological chaperones for lysosomal β-glucocerebrosidase by capillary electrophoresis. Shanmuganathan M; Britz-McKibbin P Anal Bioanal Chem; 2011 Mar; 399(8):2843-53. PubMed ID: 21286689 [TBL] [Abstract][Full Text] [Related]
11. Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-β-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease. Orwig SD; Tan YL; Grimster NP; Yu Z; Powers ET; Kelly JW; Lieberman RL Biochemistry; 2011 Dec; 50(49):10647-57. PubMed ID: 22047104 [TBL] [Abstract][Full Text] [Related]
12. New insights into the pharmacological chaperone activity of c2-substituted glucoimidazoles for the treatment of Gaucher disease. Li Z; Li T; Dai S; Xie X; Ma X; Zhao W; Zhang W; Li J; Wang PG Chembiochem; 2013 Jul; 14(10):1239-47. PubMed ID: 23775891 [TBL] [Abstract][Full Text] [Related]
13. The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. Steet RA; Chung S; Wustman B; Powe A; Do H; Kornfeld SA Proc Natl Acad Sci U S A; 2006 Sep; 103(37):13813-8. PubMed ID: 16945909 [TBL] [Abstract][Full Text] [Related]
14. Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)deoxynojirimycin. Luan Z; Higaki K; Aguilar-Moncayo M; Ninomiya H; Ohno K; García-Moreno MI; Ortiz Mellet C; García Fernández JM; Suzuki Y Chembiochem; 2009 Nov; 10(17):2780-92. PubMed ID: 19830760 [TBL] [Abstract][Full Text] [Related]
15. Rapid modifications of N-substitution in iminosugars: development of new β-glucocerebrosidase inhibitors and pharmacological chaperones for Gaucher disease. Cheng WC; Weng CY; Yun WY; Chang SY; Lin YC; Tsai FJ; Huang FY; Chen YR Bioorg Med Chem; 2013 Sep; 21(17):5021-8. PubMed ID: 23880081 [TBL] [Abstract][Full Text] [Related]
16. Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease. Sánchez-Ollé G; Duque J; Egido-Gabás M; Casas J; Lluch M; Chabás A; Grinberg D; Vilageliu L Blood Cells Mol Dis; 2009; 42(2):159-66. PubMed ID: 19167250 [TBL] [Abstract][Full Text] [Related]
17. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Bendikov-Bar I; Maor G; Filocamo M; Horowitz M Blood Cells Mol Dis; 2013 Feb; 50(2):141-5. PubMed ID: 23158495 [TBL] [Abstract][Full Text] [Related]
18. Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention. Yu Z; Sawkar AR; Whalen LJ; Wong CH; Kelly JW J Med Chem; 2007 Jan; 50(1):94-100. PubMed ID: 17201413 [TBL] [Abstract][Full Text] [Related]
19. Stereodivergent synthesis of right- and left-handed iminoxylitol heterodimers and monomers. Study of their impact on β-glucocerebrosidase activity. Stauffert F; Serra-Vinardell J; Gómez-Grau M; Michelakakis H; Mavridou I; Grinberg D; Vilageliu L; Casas J; Bodlenner A; Delgado A; Compain P Org Biomol Chem; 2017 May; 15(17):3681-3705. PubMed ID: 28401966 [TBL] [Abstract][Full Text] [Related]
20. Diltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells. Rigat B; Mahuran D Mol Genet Metab; 2009 Apr; 96(4):225-32. PubMed ID: 19167257 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]